|
Ravtansine
Ravtansine is a component of several drug conjugates and may refer to: * Cantuzumab ravtansine * Indatuximab ravtansine Indatuximab ravtansine (BT062) is an immunomodulator and antineoplastic antibody-drug conjugate. It is the anti-CD138 chimerized MAb (nBT062) linked to the maytansinoid DM4. It is being investigated as part of a treatment for multiple myeloma ... See also * Maitansine {{disambig ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Indatuximab Ravtansine
Indatuximab ravtansine (BT062) is an immunomodulator and antineoplastic antibody-drug conjugate. It is the anti-CD138 chimerized MAb (nBT062) linked to the maytansinoid DM4. It is being investigated as part of a treatment for multiple myeloma. Clinical trials Multiple Myeloma Preliminary data has been reported in 2013 from an early stage clinical trial in combination with Lenalidomide and Dexamethasone. Follow up data reported "encouraging efficacy" in December 2014. Other , it is in clinical trials for triple negative metastatic breast cancer and metastatic urinary bladder cancer. Mechanism of action CD138 (Syndecan-1) is highly overexpressed on various solid tumors and in hematological malignancies, and represents one of the most specific target antigens for identification of multiple myeloma (MM) cells. The antibody part binds to CD138 on the target cells and then the DM4 kills the cell. See also * ImmunoGen, more on DM1/DM4 and the linker used in Indatuximab ravtansine ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Cantuzumab Ravtansine
Cantuzumab ravtansine (huC242-SPDB-DM4) is an antibody-drug conjugate designed for the treatment of cancers. The humanized monoclonal antibody ''cantuzumab'' (huC242) is linked to a cytotoxic agent, ravtansine (DM4). It uses a more hindered disulfide linkage than cantuzumab mertansine. See also * Cantuzumab mertansine Cantuzumab mertansine (SB-408075; huC242-DM1) is an antibody-drug conjugate investigated to treat colorectal cancer and other types of cancer. It is a humanized monoclonal antibody, cantuzumab (huC242) linked to a cytotoxic agent, mertansine (DM ... * ImmunoGen Inc, developer of DM4 based drugs References Immunology Monoclonal antibodies Antibody-drug conjugates {{monoclonal-antibody-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |